Achieve Life Sciences Strengthens Leadership with New Directors
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a pioneering pharmaceutical firm dedicated to combating smoking cessation and nicotine dependence through its innovative drug, cytisinicline, has recently broadened its horizons. The company has appointed two distinguished individuals, Kristen Slaoui, Ph.D., and Nancy Phelan, to its Board of Directors. This strategic move comes alongside the retirement of Vaughn Himes, Ph.D., a long-serving board member, who will remain involved as a consultant.
Welcoming New Talent to the Board
Tom King, Executive Chairman of Achieve’s Board, expressed his enthusiasm over the influence that both Dr. Slaoui and Ms. Phelan will bring to the table. Their extensive knowledge in strategic transactions and healthcare innovation is expected to be invaluable as the company gears up for its first New Drug Application (NDA) submission for cytisinicline aimed at aiding smoking cessation.
Meet Dr. Kristen Slaoui
Dr. Slaoui has been making waves as the Chief Corporate Development Officer at Galderma, where she has played a pivotal role in several significant transactions, including acquiring Alastin Skincare. With a solid track record of two decades at GSK, Dr. Slaoui's expertise in pulmonary disease research is expected to greatly benefit Achieve as they navigate the complexities of pharmaceutical development.
Nancy Phelan's Expertise
Nancy Phelan is expected to bring her over 25 years of executive experience to Achieve. Currently a Senior Vice President at Trinity Life Sciences, she leads a new Center of Excellence focusing on data and digital transformation in pharmaceuticals. Her previous leadership roles at major companies such as Novartis and Pfizer, and her history of launching successful commercialization strategies, make her a strong asset for Achieve at a crucial time.
The Impact of cytisinicline
Achieve Life Sciences focuses on addressing critical health issues stemming from nicotine addiction. The company has completed extensive Phase 3 studies for smoking cessation using cytisinicline and continues its efforts to combat the impact of smoking and vaping among millions. This new leadership addition is timely as Achieve prepares for impending submissions for drug approval.
Statistics on Smoking and Vaping
Currently, around 29 million adults smoke cigarettes, with smoking being the leading cause of preventable deaths worldwide. Additionally, increasing numbers of middle and high school students are reported to be using e-cigarettes. Cytisinicline, as an investigational candidate, offers hope in effectively addressing nicotine addiction through its unique mechanism of action that interacts with nicotine receptors in the brain.
The Road Ahead
With a stringent focus on the development of cytisinicline, Achieve Life Sciences aims to submit its new drug applications and pursue clinical studies for vaping cessation in the near future. These efforts highlight the company’s commitment to tackling one of the most pressing health challenges of our time.
About Achieve Life Sciences
Achieve Life Sciences is dedicated to providing innovative solutions for smoking cessation and nicotine dependence. With completed Phase 3 studies and a clear focus on developing cytisinicline, the company continues to strive for advancements in treatments that can significantly improve public health. The inclusion of newly appointed board members enhances the strategic direction of the company during these pivotal times.
Frequently Asked Questions
What is Achieve Life Sciences focusing on?
Achieve Life Sciences focuses on the development of cytisinicline for smoking cessation and nicotine dependence.
Who are the new members of Achieve's Board of Directors?
The new members are Dr. Kristen Slaoui and Nancy Phelan, both bringing extensive experience in pharmaceuticals and healthcare.
Why is cytisinicline significant?
Cytisinicline addresses nicotine addiction, which is critical given that millions of adults both smoke and vape, creating a pressing health challenge.
What are Achieve's future plans?
Achieve plans to submit its NDA for cytisinicline and initiate further studies to address both smoking and vaping cessation.
How can I contact Achieve Life Sciences?
You can reach out to Achieve at ir@achievelifesciences.com or call 425-686-1510 for any inquiries.
